



331 Treble Cove Road  
North Billerica, MA 01862

800.362.2668  
www.lantheus.com

Dear Healthcare Provider,

We understand that there may be some confusion in the market regarding the continued supply of Xenon Xe-133 Gas. As the leading supplier of Xenon-133, Lantheus Medical Imaging wants to ensure that the U.S. medical imaging community has a secure and continuous supply of this important diagnostic imaging agent. We know that continuity of radioisotope supply remains a concern for you and the patients that you serve. We want to assure you that we are committed to ensuring reliable access to Xenon-133 to meet the needs of the medical imaging community and patients.

We are pleased to announce that Lantheus and the Institute for Radioelements in Belgium recently signed a new strategic agreement for the future supply of Xenon-133. [We have attached that press release here for your information.](#) Please share this important update with other appropriate personnel within your department and institution.


Additionally, we would like to share with you information regarding upcoming supply. As part of the required Canadian National Research Universal (NRU) reactor annual regulatory-required inspection and maintenance, Xenon-133 will not be available for the two weeks of May 11 and May 18. Lantheus anticipates normal Xenon-133 manufacture and distribution will begin again following the reactor restart. We want to make certain that you, and other healthcare providers, are aware of the two-week Xenon-133 outage so that you can appropriately schedule your patients.

We look forward to continuing to provide you and your patients access to Xenon-133 through 2016 and beyond.

Should you have any questions regarding this email or the upcoming NRU reactor maintenance period, please contact your Lantheus Nuclear Medicine

Sales Representative or Lantheus Customer Service at: 1-800-299-3431,  
Monday – Friday, 7:30 a.m. – 6:30 p.m.

Best regards,

A handwritten signature in black ink that reads "Mary Anne Heino". The signature is written in a cursive style with a large initial 'M' and 'H'.

Mary Anne Heino, Chief Operating Officer